Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: An open-label study

Licia Grazzi, Gabriella Egeo, Anne H. Calhoun, Candace K. McClure, Eric Liebler, Piero Barbanti

Research output: Contribution to journalArticle

Abstract

Background: Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling, and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy, safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual migraine/menstrually related migraine. Methods: Fifty-six enrolled subjects (menstrual migraine, 9%; menstrually related migraine, 91%), 33 (59%) of whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation adjunctively (31/51; 61%) or as monotherapy (20/51; 39%) on day −3 before estimated onset of menses through day +3 after the end of menses. Results: The number of menstrual migraine/menstrually related migraine days per month was significantly reduced from baseline (mean ± standard error, 7.2 ± 0.7days) to the end of treatment (mean ± standard error, 4.7 ± 0.5days; P < 0.001) (primary end point). Of all subjects, 39% (95% confidence interval: 26%, 54%) (20/51) had a ≥ 50% reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity (mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns. Conclusions: These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised controlled studies are warranted.

Original languageEnglish
Article number91
JournalJournal of Headache and Pain
Volume17
Issue number1
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Vagus Nerve Stimulation
Migraine Disorders
Menstruation
Safety
Analgesics
Therapeutics
Headache

Keywords

  • Menstrual migraine
  • Menstrually related migraine
  • Prophylactic treatment
  • Vagus nerve

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine : An open-label study. / Grazzi, Licia; Egeo, Gabriella; Calhoun, Anne H.; McClure, Candace K.; Liebler, Eric; Barbanti, Piero.

In: Journal of Headache and Pain, Vol. 17, No. 1, 91, 01.12.2016.

Research output: Contribution to journalArticle

@article{6d55f3db213f433e82eb3067c67e982c,
title = "Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: An open-label study",
abstract = "Background: Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling, and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy, safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual migraine/menstrually related migraine. Methods: Fifty-six enrolled subjects (menstrual migraine, 9{\%}; menstrually related migraine, 91{\%}), 33 (59{\%}) of whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation adjunctively (31/51; 61{\%}) or as monotherapy (20/51; 39{\%}) on day −3 before estimated onset of menses through day +3 after the end of menses. Results: The number of menstrual migraine/menstrually related migraine days per month was significantly reduced from baseline (mean ± standard error, 7.2 ± 0.7days) to the end of treatment (mean ± standard error, 4.7 ± 0.5days; P < 0.001) (primary end point). Of all subjects, 39{\%} (95{\%} confidence interval: 26{\%}, 54{\%}) (20/51) had a ≥ 50{\%} reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity (mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns. Conclusions: These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised controlled studies are warranted.",
keywords = "Menstrual migraine, Menstrually related migraine, Prophylactic treatment, Vagus nerve",
author = "Licia Grazzi and Gabriella Egeo and Calhoun, {Anne H.} and McClure, {Candace K.} and Eric Liebler and Piero Barbanti",
year = "2016",
month = "12",
day = "1",
doi = "10.1186/s10194-016-0684-z",
language = "English",
volume = "17",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine

T2 - An open-label study

AU - Grazzi, Licia

AU - Egeo, Gabriella

AU - Calhoun, Anne H.

AU - McClure, Candace K.

AU - Liebler, Eric

AU - Barbanti, Piero

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling, and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy, safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual migraine/menstrually related migraine. Methods: Fifty-six enrolled subjects (menstrual migraine, 9%; menstrually related migraine, 91%), 33 (59%) of whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation adjunctively (31/51; 61%) or as monotherapy (20/51; 39%) on day −3 before estimated onset of menses through day +3 after the end of menses. Results: The number of menstrual migraine/menstrually related migraine days per month was significantly reduced from baseline (mean ± standard error, 7.2 ± 0.7days) to the end of treatment (mean ± standard error, 4.7 ± 0.5days; P < 0.001) (primary end point). Of all subjects, 39% (95% confidence interval: 26%, 54%) (20/51) had a ≥ 50% reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity (mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns. Conclusions: These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised controlled studies are warranted.

AB - Background: Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling, and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy, safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual migraine/menstrually related migraine. Methods: Fifty-six enrolled subjects (menstrual migraine, 9%; menstrually related migraine, 91%), 33 (59%) of whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation adjunctively (31/51; 61%) or as monotherapy (20/51; 39%) on day −3 before estimated onset of menses through day +3 after the end of menses. Results: The number of menstrual migraine/menstrually related migraine days per month was significantly reduced from baseline (mean ± standard error, 7.2 ± 0.7days) to the end of treatment (mean ± standard error, 4.7 ± 0.5days; P < 0.001) (primary end point). Of all subjects, 39% (95% confidence interval: 26%, 54%) (20/51) had a ≥ 50% reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity (mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns. Conclusions: These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised controlled studies are warranted.

KW - Menstrual migraine

KW - Menstrually related migraine

KW - Prophylactic treatment

KW - Vagus nerve

UR - http://www.scopus.com/inward/record.url?scp=84989953094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989953094&partnerID=8YFLogxK

U2 - 10.1186/s10194-016-0684-z

DO - 10.1186/s10194-016-0684-z

M3 - Article

AN - SCOPUS:84989953094

VL - 17

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

M1 - 91

ER -